MetLife Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

MetLife Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,819	Closed	-$110K	–	2889
2025 Q3	$110K	Buy	+2,819	New	+$80.3K	﹤0.01%	2613
2023 Q3	–	Sell	-560	Closed	-$57K	–	2993
2023 Q2	$57K	Hold	560	–	–	﹤0.01%	2888
2023 Q1	$99K	Sell	560 -184	-25%	-$61.6K	﹤0.01%	2559
2022 Q4	$288K	Hold	744	–	–	﹤0.01%	2017
2022 Q3	$251K	Buy	744 +89	+14%	+$32.2K	﹤0.01%	2141
2022 Q2	$215K	Sell	655 -103	-14%	-$36.1K	﹤0.01%	2267
2022 Q1	$331K	Buy	758 +252	+50%	+$103K	﹤0.01%	2037
2021 Q4	$222K	Hold	506	–	–	﹤0.01%	1990
2021 Q3	$281K	Hold	506	–	–	﹤0.01%	1861
2021 Q2	$260K	Hold	506	–	–	﹤0.01%	1986
2021 Q1	$395K	Hold	506	–	–	﹤0.01%	1661
2020 Q4	$276K	Hold	506	–	–	﹤0.01%	1810
2020 Q3	$232K	Hold	506	–	–	﹤0.01%	1779
2020 Q2	$311K	Hold	506	–	–	﹤0.01%	1635
2020 Q1	$241K	Hold	506	–	–	﹤0.01%	1591
2019 Q4	$293K	Hold	506	–	–	﹤0.01%	1766
2019 Q3	$333K	Buy	506 +70	+16%	+$58.2K	﹤0.01%	1639
2019 Q2	$337K	Hold	436	–	–	﹤0.01%	1724
2019 Q1	$308K	Hold	436	–	–	﹤0.01%	1739
2018 Q4	$204K	Buy	+436	New	+$281K	﹤0.01%	1897
2018 Q3	–	Sell	-319	Closed	-$220K	–	2635
2018 Q2	$220K	Hold	319	–	–	﹤0.01%	1886
2018 Q1	$142K	Hold	319	–	–	﹤0.01%	2070
2017 Q4	$140K	Buy	+319	New	+$145K	﹤0.01%	2107

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

MetLife Investment Management's TVRD Position: Q4 2025 in Review

MetLife Investment Management sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 2,819 shares — an estimated $110K sold.

MetLife Investment Management first reported a position in TVRD in Q4 2017 and held it in 23 quarters. The position peaked at $395K in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

MetLife Investment Management reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
MetLife Investment Management sold 2,819 Tvardi Therapeutics shares in Q4 2025, an estimated $110K.
MetLife Investment Management first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 23 quarters.
MetLife Investment Management's Tvardi Therapeutics position peaked at $395K in Q1 2021.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.